



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beechem et al.)
Serial No.: 10/666,291) Examiner: Not Yet Known
Filed: September 17, 2003) Group Art Unit: Not Yet Known
For: **Antibody Complexes and Methods**) **TRANSMITTAL LETTER**
 for Immunolabeling)
)

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith are the following documents in the above-identified application.

- Supplemental Information Disclosure Statement
- Substituted USPTO Form 1449
- Cited References A53-A54 and C13-C24
- Fee Transmittal Form (PTO/SB/17)
- Return Postcard (Postage Prepaid)

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED TO AS BEING ATTACHED OR ENCLOSED HEREWITHE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON April 6, 2004 AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450.

By me d. s., Michael A. Sennett

Beechem et al.
10/666,291

Respectfully submitted,

Date: April 6, 2004

Karen J. Anderson

Karen J. Anderson, Ph.D.
Reg. No. 51,061

Molecular Probes, Inc.
29851 Willow Creek
Eugene, Oregon, 97402
Phone: (541) 335-0203
Facsimile: (541) 335-0188

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

APR 12 2004

FEE TRANSMITTAL
for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

Complete if Known

Application Number	10/666,291
Filing Date	September 14, 2003
First Named Inventor	Joseph Beechem
Examiner Name	
Art Unit	
Attorney Docket No.	

METHOD OF PAYMENT (check all that apply)
 Check Credit card Money Order Other None
 Deposit Account:

Deposit Account Number	13-3900
Deposit Account Name	Molecular Probes, Inc.

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments

Charge any additional fee(s) or any underpayment of fee(s)

Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION**1. BASIC FILING FEE**

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code (\$)	Fee Code (\$)		
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1)		(\$ 0.00)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	=
Multiple Dependent	- 3** =	X	=

Large Entity	Small Entity	Fee Description
Fee Code (\$)	Fee Code (\$)	
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$ 0.00)

**or number previously paid, if greater; For Reissues, see above

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath			
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet			
1053 130	1053 130	Non-English specification			
1812 2,520	1812 2,520	For filing a request for ex parte reexamination			
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action			
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action			
1251 110	2251 55	Extension for reply within first month			
1252 420	2252 210	Extension for reply within second month			
1253 950	2253 475	Extension for reply within third month			
1254 1,480	2254 740	Extension for reply within fourth month			
1255 2,010	2255 1,005	Extension for reply within fifth month			
1401 330	2401 165	Notice of Appeal			
1402 330	2402 165	Filing a brief in support of an appeal			
1403 290	2403 145	Request for oral hearing			
1451 1,510	1451 1,510	Petition to institute a public use proceeding			
1452 110	2452 55	Petition to revive - unavoidable			
1453 1,330	2453 665	Petition to revive - unintentional			
1501 1,330	2501 665	Utility issue fee (or reissue)			
1502 480	2502 240	Design issue fee			
1503 640	2503 320	Plant issue fee			
1460 130	1460 130	Petitions to the Commissioner			
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)			
1806 180	1806 180	Submission of Information Disclosure Stmt			180.00
8021 40	8021 40	Recording each patent assignment per property (times number of properties)			
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))			
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))			
1801 770	2801 385	Request for Continued Examination (RCE)			
1802 900	1802 900	Request for expedited examination of a design application			

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 180.00)**SUBMITTED BY**

Name (Print/Type)	Koren J. Anderson	Registration No. (Attorney/Agent)	51,061	Telephone	541-335-0203
Signature	Karen J. Anderson			Date	4/6/04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beechem et al.)
Serial No.: 10/666,291) Examiner: Not Yet Known
Filed: September 17, 2003) Group Art Unit: Not Yet Known
For: **Antibody Complexes and Methods**) **SUPPLEMENTAL INFORMATION**
for Immunolabeling) **DISCLOSURE STATEMENT**

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97(c) The Supplemental Information Disclosure Statement (IDS) being transmitted herewith is being filed after the mailing date of the first Office Action on the merits but before the mailing date of an action that effectively closes prosecution on the merits. Accordingly, a fee specified in CFR 1.17(p) and the statement specified in paragraph (e) of 37 CFR 1.97 is hereby submitted with this IDS.

In accordance with 37 CFR 1.97(e)(2), Applicants hereby certify that no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application and no item of information contained in the information disclosure statement was known more than three months prior to filing of this IDS.

Applicants, respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. The Examiner is requested to initial and return the enclosed PTO-1449 form in accordance with MPEP §609.

This Information Disclosure Statement pursuant to 37 CFR 1.97 is not to be construed as a representation that: (1) a search has been made; (2) the above information constitutes prior art to the subject invention. Accordingly, it is requested that the Examiner consider the enclosed references.

04/14/2004 BABRAHA1 00000136 133900 10666291
01 FC:1806 180.00 DA

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED TO AS BEING ATTACHED OR ENCLOSED HEREWITHE ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON April 6, 2004 AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450.
By Michael A. Sennett

Beechem et al.
10/666,291

Respectfully submitted,

Date: April 6, 2004

Molecular Probes, Inc.
29851 Willow Creek Road
Eugene, Oregon, 97402
Phone: (541) 335-0203
Facsimile: (541) 335-0188

Koren J. Anderson
Koren J. Anderson, Ph.D.
Reg. No. 51,061

O I P E
APR 12 2004

Page 1 of 1

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Docket:

Ser: 10/666,291

Applicant: Beechem, et al.

Filed:
September 17, 2003

Group:

U.S. PATENT DOCUMENTS

Init.*	Cite No.	Number	Date	Name	Class	Sub	Filed
	A53	US 2002/0064794	05/30/02	Leung et al.			
	A54	US 2002/0077487	06/20/02	Leung et al.			

NON PATENT LITERATURE DOCUMENTS

Init.*	Cite No.	Name of Author, Title of the Article, Title of the Item, Date, Page, Volume-Issue Number
	C13	Matayoshi, E. D., G. T. Wang, et al. (1990). "Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer." <u>Science</u> 247 (4945): 954-8.
	C14	dos Remedios, C. G. and P. D. Moens (1995). "Fluorescence resonance energy transfer spectroscopy is a reliable "ruler" for measuring structural changes in proteins. Dispelling the problem of the unknown orientation factor." <u>J Struct Biol</u> 115 (2): 175-85.
	C15	Selvin, P. R. (1995). "Fluorescence resonance energy transfer." <u>Methods Enzymol</u> 246 : 300-34.
	C16	Zhang, K., D. Baeckstrom, et al. (1994). "A secreted mucin carrying sialyl-Lewis a from colon carcinoma cells binds to E-selectin and inhibits HL-60 cell adhesion." <u>Int J Cancer</u> 59 (6): 823-9.
	C17	Capo, C., Z. Mishal, et al. (1983). "Dimethylsulphoxide induction of the murine macrophage-like line P388D1: change of phagocytic ability and cell surface properties." <u>J Cell Sci</u> 64 : 281-93.
	C18	Davidson-Moncada, J. K., G. Lopez-Lluch, et al. (2002). "Involvement of protein kinase D in Fc gamma-receptor activation of the NADPH oxidase in neutrophils." <u>Biochem J</u> 363 (Pt 1): 95-103.
	C19	Kimura, S., M. Numaguchi, et al. (2000). "High galactosylation of oligosaccharides in umbilical cord blood IgG, and its relationship to placental function." <u>Clin Chim Acta</u> 299 (1-2): 169-77.
	C20	Marshall, L. R., F. E. Brogden, et al. (1994). "Antenatal platelet antibody testing by flow cytometry--results of a pilot study." <u>Transfusion</u> 34 (11): 961-5.
	C21	Friedman, M. G. (1981). "A population screening test for antibody to measles virus." <u>Isr J Med Sci</u> 17 (11): 1045-50.
	C22	Zhang, J. H., T. D. Chung, et al. (1999). "A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays." <u>J Biomol Screen</u> 4 (2): 67-73.
	C23	Kricka, L. J. (1992). <i>Nonisotopic DNA Probe Techniques</i> . San Diego: Academic Press, Inc.
	C24	<i>Decision on Appeal: Hearing Before the Board of Patent Appeals and Interferences, United States Patent and Trademark Office</i> , Appeal No. 95-4481, Application 07/911,667.

EXAMINER:

DATE:

*Examiner: Initial if considered, whether or not in conformance with MPEP 60; draw line through cite if not in conformance and not considered. Send copy.